Pyoderma gangrenosum study pilot registry: The first step to a better understanding

Area of Science:

• Dermatology
• Clinical Research
• Patient Registries

Background:

• Pyoderma gangrenosum (PG) is a rare, chronic neutrophilic dermatosis characterized by painful ulcerative lesions.
• Limited prospective data exists on PG patient demographics, treatments, and outcomes.
• A physician-driven registry is needed to systematically collect comprehensive PG patient information.

Purpose of the Study:

• To develop and pilot a physician-driven patient registry for pyoderma gangrenosum (PG).
• To summarize baseline demographics, medical history, treatments, and outcomes in PG patients.
• To identify factors associated with healing in PG patients.

Main Methods:

• Prospective data collection from December 2019 to July 2021 at a single academic institution.
• Inclusion criteria: PG diagnosis with a PARACELSUS score of at least 10 for ulcerative cases.
• Data collected included demographics, comorbidities, treatments, healing outcomes, hospitalizations, and recurrences.

Main Results:

• The Pyoderma Gangrenosum Study (PYGAS) Registry included 52 patients with 56 lesions across four subtypes.
• Ulcerative PG was the most common subtype (41 lesions); most referrals came from dermatologists.
• Systemic immunomodulators at baseline were significantly associated with healing (P=0.048).

Conclusions:

• This pilot study demonstrates the feasibility of a physician-driven PG registry.
• Systemic immunomodulators show a positive impact on pyoderma gangrenosum healing.
• Standardization of wound care and data collection is essential for future clinical studies in PG.